The use of stable prostaglandins to investigate prostacyclin (PGI2)-binding sites and PGI2-sensitive adenylate cyclase in human platelet membranes.

[1]  J. Bockaert,et al.  Characteristics of the β 1- and β 2-adrenergic-sensitive adenylate cyclases in glial cell primary cultures and their comparison with β 2-adrenergic-sensitive adenylate cyclase of meningeal cells , 1981, Brain Research.

[2]  I. Blair,et al.  THE BINDING OF [3H]‐PROSTACYCLIN TO MEMBRANES OF A NEURONAL SOMATIC HYBRID , 1981, British journal of pharmacology.

[3]  G. Prior,et al.  Prostaglandin I2 receptors in a particulate fraction of platelets of various species. , 1980, Biochemical pharmacology.

[4]  J. Vane,et al.  Effects of prostacyclin and a stable analogue, 6β-PGI1, on gastric acid secretion, mucosal blood flow, and blood pressure in conscious dogs , 1979 .

[5]  A. Schafer,et al.  Identification of platelet receptors for prostaglandin I2 and D2. , 1979, The Journal of biological chemistry.

[6]  K. C. Nicolaou,et al.  Selective binding site for [3H]prostacyclin on platelets. , 1979, The Journal of clinical investigation.

[7]  J. Vane,et al.  The relative activity of prostacyclin (PGI2) and a stable analogue 6β‐PGI1 on the gastrointestinal and cardiovascular systems , 1978, The Journal of pharmacy and pharmacology.

[8]  J. Vane,et al.  Comparison of the effects of prostacyclin (PGI2), prostaglandin E1 and D2 on platelet aggregation in different species. , 1978, Prostaglandins.

[9]  R. A. Johnson,et al.  Synthesis and sterochemistry of prostacyclin and synthesis of 6-ketoprostagliandin F1alpha. , 1977, Journal of the American Chemical Society.

[10]  J. Vane,et al.  Effects of prostacyclin (PGX) on cyclic AMP concentrations in human platelets. , 1977, Prostaglandins.

[11]  O. V. Miller,et al.  Modulation of human platelet adenylate cyclase by prostacyclin (PGX). , 1977, Prostaglandins.

[12]  R. A. Johnson,et al.  The chemical structure of prostaglandin X (prostacyclin). , 1976, Prostaglandins.

[13]  J. Vane,et al.  An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation , 1976, Nature.

[14]  C. Londos,et al.  A highly sensitive adenylate cyclase assay. , 1974, Analytical biochemistry.

[15]  I. Blair,et al.  Epoprostenol (prostacyclin, PGI2) binding and activation of adenylate cyclase in platelets of diabetic and control subjects. , 1983, British journal of clinical pharmacology.